In the late 1990s, an in vitro study with PC-3 and LNCaP prostate cancer cell lines showed that MK886, a FLAP-binding 5-LOX inhibitor, leads to apoptosis due to the inhibition of 5-LOX activities. The gene discussed is ALOX5; the disease is prostate carcinoma.